Literature DB >> 34381269

High-Dose Daptomycin Is Well Tolerated via 2-Minute IV Push Administration.

Christian M Gill1, Rachel M Kenney1, Charles T Makowski1, Susan L Davis1,2.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the safety of administering high-dose daptomycin (HDD; > 6 mg/kg actual body weight) as a 2-minute intravenous (IV) push (IVP) compared to traditional 30-minute IV piggyback (IVPB) infusion.
METHODS: Retrospective cohort study comparing patients receiving HDD as an IVP or IVPB infusion. The primary outcome was the proportion of patients with a documented infusion-related reaction (IRR) to daptomycin.
RESULTS: Three hundred patients were included in the final analysis, 200 patients received IVP, and 100 patients received IVPB representing a total of 1697 administrations. Median (IQR) daptomycin dose was IVP 700 mg (550-900) and IVPB 700 mg (600-900), with mg/kg doses of 8.2 (7.9-10) and 8.3 (8-10), respectively. After adjudication, IRR occurred in 1% of subjects in each treatment group.
CONCLUSIONS: This study provides data in more than 1100 administrations of HDD administered via IVP. Infusion-related reactions were documented in 1% of patients regardless of infusion method, suggesting comparable safety to traditional infusion methods. This practice may be useful during fluid shortage and in the outpatient setting.
© The Author(s) 2019.

Entities:  

Keywords:  daptomycin; infusion intravenous; medication safety; pharmaceutical preparations

Year:  2020        PMID: 34381269      PMCID: PMC8326862          DOI: 10.1177/0018578719897076

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  11 in total

1.  Drug shortages and patient safety: an overview of essential information for the infusion nurse.

Authors:  Milena M McLaughlin; Erik W Skoglund
Journal:  J Infus Nurs       Date:  2015 May-Jun

2.  ASHP guidelines on managing drug product shortages.

Authors:  Erin R Fox; Milena M McLaughlin
Journal:  Am J Health Syst Pharm       Date:  2018-07-30       Impact factor: 2.637

3.  Safety and efficacy of daptomycin in outpatient parenteral antimicrobial therapy: a prospective and multicenter cohort study (DAPTODOM trial).

Authors:  Carlos Cervera; Pedro Sanroma; Víctor González-Ramallo; Cristina García de la María; Gemma Sanclemente; Nieves Sopena; Marcos Pajarón; Antonio Segado; Manuel Mirón; Francisco Antón; Andima Basterretxea; Ana Cuende; José M Miró
Journal:  Infect Dis (Lond)       Date:  2016-11-08

4.  Saline Shortages - Many Causes, No Simple Solution.

Authors:  Maryann Mazer-Amirshahi; Erin R Fox
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Association of Higher Daptomycin Dose (7 mg/kg or Greater) with Improved Survival in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  Tristan T Timbrook; Aisling R Caffrey; Megan K Luther; Vrishali Lopes; Kerry L LaPlante
Journal:  Pharmacotherapy       Date:  2018-01-08       Impact factor: 4.705

7.  Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients.

Authors:  Nicholas S Britt; Emily M Potter; Nimish Patel; Molly E Steed
Journal:  Clin Infect Dis       Date:  2017-03-01       Impact factor: 9.079

8.  Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.

Authors:  Sujata M Bhavnani; Christopher M Rubino; Paul G Ambrose; George L Drusano
Journal:  Clin Infect Dis       Date:  2010-06-15       Impact factor: 9.079

9.  In vivo pharmacodynamic activity of daptomycin.

Authors:  Nasia Safdar; David Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection.

Authors:  Abhijit Chakraborty; Sandip Roy; Juergen Loeffler; Ricardo L Chaves
Journal:  J Antimicrob Chemother       Date:  2009-04-22       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.